FBRX

Forte Biosciences, Inc. (NASDAQ:FBRX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Dallas, Texas. The company went public through an initial public offering in April 2017. Forte operates as a development-stage biotechnology firm focused on creating treatments for autoimmune diseases, with its primary asset being the FB-102 program targeting conditions such as vitiligo and alopecia areata. As a clinical-stage company, Forte has not yet generated revenue from product sales and remains in the research and development phase of bringing its therapeutic candidates to market.